Harvard Bio Lab Secures $39M PE Funding, Ushering in Novel Research Model

İş Private Equity, a Turkish firm, has invested $39M in a Harvard genetics and metabolism lab led by Prof. Gökhan Hotamışlıgil. This funding will support the lab’s research and simultaneously seed a new biotech, Enlila, focused on developing metabolic disease therapies.

The investment represents a potentially transformative model for academic research funding, particularly given recent federal funding cuts. İş PE will also provide undisclosed funding for promising drug candidates emerging from the lab and transitioning to Enlila.

While the investment sum is relatively modest in the context of larger PE deals, it highlights an alternative funding mechanism crucial in the face of evolving scientific funding landscapes.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.